Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus

Antiviral Chemistry and Chemotherapy

Volumn 10, Issue 5, 1999, Pages 233-240

  Mao, Chen ^a   Sudbeck, Elise A ^a   Venkatachalam, T K ^a   Uckun, Fatih M ^a  

^a PARKER HUGHES INSTITUTE   (United States)

Author keywords

HIV; Reverse transcriptase; Thiourea

Indexed keywords

DELAVIRDINE; EMIVIRINE; HI 280; HI 281; N [2 (2 FLUOROPHENETHYL)] N' [2 (5 BROMOPYRIDYL)]THIOUREA; N [2 (2,5 DIMETHOXYPHENYLETHYL)] N' [2 (5 BROMOPYRIDYL)]THIOUREA; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIOUREA DERIVATIVE; TROVIRDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; COMPUTER MODEL; DRUG DESIGN; DRUG POTENCY; DRUG SENSITIVITY; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032821101     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029901000502     Document Type: Article

References (28)

1. Ahgren C, Backro K, Bell FW, Cantrell AS, Clemens M, Colacino JM, Deeter JB, Engelhardt JAMH, Jaskunas SR, Johansson NG et al. (1995) The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 39:1329-1335.
2. Bell FW, Cantrell AS, Hogberg M, Jaskunas SR, Johansson NG, Jordan CL, Kinnick MD, Lind P, Morin JM Jr, Noreen R et al. (1995) Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. Journal of Medicinal Chemistry 38:4929-4936.
3. Bohm HJ (1992) LUDI: rule-based automatic design of new substituents tor enzyme inhibitor leads. Journal of Computer Aided Molecular Design 6:593-606.
4. Bohm HJ (1994) The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. Journal of Computer Aided Molecular Design 8:243-256.
5. Cantrell AS, Engelhardt P, Hogberg M, Jaskunas SR, Johansson NG, Jordan CL, Kangasmetsa J, Kinnick MD, Lind P, Morin JM Jr et al. (1996) Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs. Journal of Medicinal Chemistry 39:4261-4274.
6. Connolly ML (1983) Solvent-accessible surfaces of proteins and nucleic acids. Science 221:709-713.
7. Danel K, Larsen E, Pedersen EB, Vestergaard BF & Nielsen C (1996) Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. Journal of Medicinal Chemistry 39:2427-2431.
8. Danel K, Nielsen C & Pedersen EB (1997) Anti-HIV active naphthyl analogues of HEPT and DABO. Acta Chemica Scandinavica 51:426-430.
9. Danel K, Pedersen EB & Nielsen C (1998) Synthesis and anti-HIV-1 activity of novel 2,3-dihydro-7H-thiazolo[3,2-a]pyrimidin-7-ones. Journal of Medicinal Chemistry 41:191-198.
10. Esnouf RM, Ren J, Hopkins AL, Ross CK, Jones EY, Stammers DK & Stuart DI (1997) Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations tor this nonnucleoside inhibitor. Proceedings of the National Academy of Sciences, USA 94:3984-3989.
11. Heinisch G, Matuszczak B, Pachler S & Rakowitz D (1997) The inhibitory activity of diazinyl-substituted thiourea derivatives on human immunodeficiency virus type 1 reverse transcriptase. Antiviral Chemistry & Chemotherapy 8:443-446.
12. Hopkins AL, Ren J, Esnouf RM, Willcox BE, Jones EY, Ross C, Miyasaka T, Walker RT, Tanaka H, Stammers DK & Stuart DI (1996) Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. Journal of Medicinal Chemistry 39:1589-1600.
13. Hsiou Y, Das K, Ding J, Clark ADJ, Kleim JP, Rosner M, Winkler I, Riess G, Hughes SH & Arnold E (1998) Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. Journal of Molecular Biology 284:313-323.
14. Huang H, Chopra R, Verdine GL & Harrison SC (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
15. Kroeger Smith MB, Rouzer CA, Taneyhill LA, Smith NA, Hughes SH, Boyer PL, Janssen PA, Moereels H, Koymans L, Arnold E et al. (1995) Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity. Protein Science 4:2203-2222.
16. Larder BA, Kellam P & Kemp SD (1993) Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 365:451-453.
17. Mai A, Artica M, Sbardella G, Quartarone S, Massa S, Loi AG, Montis AD, Scintu F, Putzolu M & La Colla P (1997) Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. Journal of Medicinal Chemistry 40:1447-1454.
18. Mao C, Vig R, Venkatachalam TK, Sudbeek EA & Uckun FM (1998) Structure-based design of N-[2-(1-piperidinylethyl)-N′-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)-N′-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic and Medicinal Chemistry Letters 8:2213-2218.
19. Miles SA (1997) HIV infection and AIDS: new biology, therapeutic advances, and clinical implications. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 16 (Suppl. 1):S1-S2.
20. Nicholls A, Sharp K & Honig B (1991) Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins, Structure, Function, and Genetics 11:281-296.
21. NunbergJH, Schleif WA, Boots EJ, O'Brien JA, Quintero JC, Hoffman AM, Emini EA & Goldman ME (1991) Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. Journal of Virology 65:4887-4892.
22. Ren J, Esnouf R, Hopkins A, Ross C, Jones Y, Stammers D & Smart D (1995a) The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 3:915-926.
23. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Darby G, Jones Y, Stuart D &Stammers D (1995b) High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Structural Biology 2:293-302.
24. Richman D, Shih CK, Lowy I, Rose J, Prodanovic P, Goff S & Griffin J (1991) Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proceedings of the National Academy of Sciences, USA 88:11241-11245.
25. Sudbeck EA, Mao C, Vig R, Venkatachalam TK, Tuel-Ahlgren L & Uckun FM (1998) Structure-based design of novel dihydroalkoxy-benzyloxopyrimidine (DABO) derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase. Antimicrobial Agents and Chemotherapy 42:3225-3233.
26. Tanaka H, Baba M, Hayakawa H, Sakamaki T, Miyasaka T, Ubasawa M, Takashima H, Sekiya K, Nitta I, Shigeta S, Walker RT, Balzarini J & De Clercq E (1991) A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5-or 6-substiruted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). Journal of Medicinal Chemistry 34:349-357.
27. Vig R, Mao C, Venkatachalam TK, Tuel-Ahlgren L, Sudbeck EA and Uckun FM (1998a) Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase. Bioorganic and Medicinal Chemistry Letters 6:1789-1797.
28. Vig R, Mao C, Venkatachalam TK, Tuel-Ahlgren L, Sudbeck EA & Uckun FM (1998b) 5-alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series. Bioorganic and Medicinal Chemistry Letters 8:1461-1466.